Classes
DEA Class; Rx
Common Brand Names; Sular
- Calcium Channel Blockers;
- Calcium Channel Blockers, Dihydropyridine
Description
Indications
Indicated for the treatment of hypertension.
Contraindications
Hypersensitivity to nisoldipine or other calcium channel blockers
Adverse Effects
- Peripheral edema (22%)
- Dizziness (5%)
- Palpitation (3%)
- Vasodilation (4%)
- Increased severity of angina (1.5%)
- Nausea (2%)
- Pharyngitis (5%)
- Sinusitis (3%)
- Gingival hyperplasia
- Colitis
- Anemia
- Alopecia
- Anorexia
- Anxiety
- Ischemia
- Diabetes mellitus
- Dyspepsia
- Dysphagia
Warnings
Use caution in CHF, aortic stenosis, hypotension (initially or after dose increases), persistent progressive dermatologic reactions, exacerbation of angina (during initiation of treatment, after dose increased, beta blocker withdrawal), liver impairment
Reflex tachycardia resulting in angina and/or MI in patients with obstructive coronary disease reported
Peripheral edema may occur within 2-3 weeks of initiating therapy
Hypotension with or without syncope is possible (particularly with severe aortic stenosis)
Do not take with high fat meal or grapefruit products
Start at lower dose with liver/kidney dysfunction, elderly
Pregnancy and Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk, use caution
Maximum Dosage
34 mg/day PO.
34 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Nisoldipine
tablet, extended-release (generic)
- 8.5mg
- 17mg
- 20mg
- 25.5mg
- 30mg
- 34mg
- 40mg
tablet, extended-release (Sular, new hydrogel ER formulation)
- 8.5mg
- 17mg
- 34mg